LRIG1 and breast cancer: We used the Mantel-Cox log-rank test to calculate the significance level of differences between OS or MFS distributions for the different LRIG1 copy number categories (loss, normal, or gain) for the whole cohort or early-stage breast cancer (stages I and II), for the entire study period, and for 5 years and 10 years (Fig. 2).